Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.

OBJECTIVE--To review the importance of heart rate variability analysis in left ventricular dysfunction and heart failure and to assess the effects of drug treatment. In patients with left ventricular dysfunction or heart failure, a low heart rate variability is a strong predictor of a low probability of survival. Because drug treatment in these patients has rapidly changed over the past two decades, the effect of these drugs on heart rate variability needs special attention. DESIGN--A study of published reports to give an overview of heart rate variability in patients with left ventricular dysfunction or heart failure and how it is affected by drug treatment. RESULTS--Analysis of heart rate variability provides an easily obtained early marker for progression of disease. It seems to be more closely related to the degree of neurohumoral activation than to haemodynamic variables. Cardiovascular drugs may either stimulate or inhibit the degree of neurohumoral activation, and the effects of pharmacological intervention can be closely monitored with this method. CONCLUSIONS--The analysis of heart rate variability, including spectral analysis, is a novel non-invasive way to obtain potentially useful clinical information in patients with reduced left ventricular function. The effects of drug treatment on heart rate variability are in general consistent with their long-term effects in left ventricular dysfunction and heart failure.

[1]  F. Verheugt,et al.  Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). , 1994, European heart journal.

[2]  R. Peters,et al.  Circadian pattern of arrythmic death in patients receiving encainide, Flecainide or moricizine in the cardiac arrhythmia☆ , 1994 .

[3]  R. Peters,et al.  Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). , 1994, Journal of the American College of Cardiology.

[4]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[5]  P. Armstrong,et al.  Medical Advances in the Treatment of Congestive Heart Failure , 1993, Circulation.

[6]  W. Stevenson,et al.  Sudden Death Prevention in Patients With Advanced Ventricular Dysfunction , 1993, Circulation.

[7]  J. Brouwer,et al.  Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). , 1993, Journal of the American College of Cardiology.

[8]  Craig D. Miller,et al.  Management of Patients With Intramural Hematoma of the Thoracic Aorta , 1993, Circulation.

[9]  B. Uretsky,et al.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.

[10]  H. Crijns,et al.  Electrocardiographic patterns relative to initiating mechanisms of exercise-induced ventricular tachycardia. , 1993, American heart journal.

[11]  J. Fleiss,et al.  Effects of digoxin and enalapril on heart period variability and response to head-up tilt in normal subjects. , 1993, American Journal of Cardiology.

[12]  J. Parameshwar,et al.  The role of calcium antagonists in the treatment of chronic heart failure. , 1993, European heart journal.

[13]  P. Bjerregaard,et al.  Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. , 1993, The American journal of cardiology.

[14]  H. Crijns,et al.  Mode of death in patients with congestive heart failure: comparison between possible candidates for heart transplantation and patients with less advanced disease. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  P. Binkley,et al.  Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. , 1993, Journal of the American College of Cardiology.

[16]  G. PORENTA,et al.  Prognostic Value of Heart Rate Variability in Patients Awaiting Cardiac Transplantation , 1992, Pacing and clinical electrophysiology : PACE.

[17]  F. Lombardi,et al.  Autonomic effects of antiarrhythmic drugs and their importance. , 1992, European heart journal.

[18]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[19]  M G Kienzle,et al.  Clinical, hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. , 1992, The American journal of cardiology.

[20]  M. Rousseau,et al.  Effects of Intravenous Epinine Administration on Left Ventricular Systolic Performance, Coronary Hemodynamics, and Circulating Catecholamines in Patients with Heart Failure , 1992, Journal of cardiovascular pharmacology.

[21]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[22]  D. Ferguson,et al.  Digoxin. A neurohormonal modulator in heart failure? , 1991, Circulation.

[23]  M. A. Plant Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[24]  P. Binkley,et al.  Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. , 1991, Journal of the American College of Cardiology.

[25]  A. Malliani,et al.  Cardiovascular Neural Regulation Explored in the Frequency Domain , 1991, Circulation.

[26]  Peter J. Schwartz,et al.  Heart rate variability in patients with ventricular arrhythmias: Effect of antiarrhythmic drugs , 1991 .

[27]  P Maison-Blanche,et al.  Heart rate variability in left ventricular hypertrophy and heart failure, and the effects of beta-blockade. A non-spectral analysis of heart rate variability in the frequency domain and in the time domain. , 1991, European heart journal.

[28]  T. Bjurö,et al.  Role of central nervous beta-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone , 1991 .

[29]  J. Fleiss,et al.  Effect of atenolol and diltiazem on heart period variability in normal persons. , 1991, Journal of the American College of Cardiology.

[30]  A J Camm,et al.  Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. , 1991, British heart journal.

[31]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[32]  I. Abrass,et al.  Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. , 1990, The American journal of cardiology.

[33]  G. Guyatt,et al.  To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. , 1990, The American journal of medicine.

[34]  W. Craelius,et al.  Use of heart rate spectral analysis to study the effects of calcium channel blockers on sympathetic activity after myocardial infarction. , 1990, American heart journal.

[35]  U. Dahlström,et al.  Neuroendocrine response in acute heart failure and the influence of treatment. , 1989, European heart journal.

[36]  M. Packer Pathophysiological Mechanisms Underlying the Adverse Effects of Calcium Channel‐Blocking Drugs in Patients With Chronic Heart Failure , 1989, Circulation.

[37]  G. Casolo,et al.  Decreased spontaneous heart rate variability in congestive heart failure. , 1989, The American journal of cardiology.

[38]  D. Ferguson,et al.  Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. , 1989, Circulation.

[39]  M. Memo,et al.  Inhibition of Aldosterone Secretion by Dopamine, Ibopamine, and Dihydroergotoxine in Patients with Congestive Heart Failure , 1989, Journal of cardiovascular pharmacology.

[40]  P. Schwartz,et al.  Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. , 1988, Circulation.

[41]  A. Rumley,et al.  Neuroendocrine activation after acute myocardial infarction. , 1988, British heart journal.

[42]  R J Cohen,et al.  Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. , 1988, The American journal of cardiology.

[43]  P. Reddy,et al.  Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. , 1987, Chest.

[44]  J. Miller,et al.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. , 1987, The American journal of cardiology.

[45]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[46]  R. Cohen,et al.  Hemodynamic regulation: investigation by spectral analysis. , 1985, The American journal of physiology.

[47]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[48]  G. Varigos,et al.  Sinus Arrhythmia in Acute Myocardial Infarction , 1978, The Medical journal of Australia.

[49]  B Lown,et al.  Neural activity and ventricular fibrillation. , 1976, The New England journal of medicine.

[50]  R. Gillis Digitalis: A neuroexcitatory drug. , 1975, Circulation.